Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Payables (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Payables for 15 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • Quarterly Payables rose 67.75% to $8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.1 million through Dec 2025, up 67.75% year-over-year, with the annual reading at $8.1 million for FY2025, 67.75% up from the prior year.
  • Payables hit $8.1 million in Q4 2025 for Cardiff Oncology, up from $2.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $8.1 million in Q4 2025 to a low of $396000.0 in Q3 2021.
  • Historically, Payables has averaged $3.0 million across 5 years, with a median of $2.3 million in 2023.
  • Biggest five-year swings in Payables: crashed 56.73% in 2021 and later skyrocketed 259.85% in 2022.
  • Year by year, Payables stood at $1.4 million in 2021, then soared by 35.93% to $2.0 million in 2022, then rose by 0.51% to $2.0 million in 2023, then soared by 145.22% to $4.8 million in 2024, then soared by 67.75% to $8.1 million in 2025.
  • Business Quant data shows Payables for CRDF at $8.1 million in Q4 2025, $2.4 million in Q3 2025, and $6.0 million in Q2 2025.